Table 2 Current pharmacological treatment in the T2D patients (n = 28)
From: Rho kinase cascade activation in circulating leukocytes in patients with diabetes mellitus type 2
Pharmacological treatment | |
|---|---|
Metformin (%) | 89 |
Only metformin (%) | 14 |
Other oral hypoglicemic drug (%) | 43 |
Metformin + Other oral hypoglicemic drug (%) | 38 |
Insulin (%) | 57 |
Only insulin (%) | 4 |
Insulin + Metformin (%) | 50 |
Insulin + any oral hypoglicemic drug (%) | 54 |
ACE inhibitors (%) | 21 |
Angiotensin receptor blockers (%) | 75 |
Betablockers (%) | 36 |
Thiazides (%) | 25 |
Statins (%) | 71 |
Aspirin (%) | 43 |